

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended): A method for softening expression lines on a face and/or forehead in need thereof, comprising topically applying ~~a composition~~ to one or more zones of the face or forehead marked with expression lines a composition comprising a physiologically acceptable medium, and 0.1% to 10% by weight of adenosine with respect to the total composition weight, in an amount of effective to provide a relaxing effect on skin associated with the expression lines, thereby softening the expression lines.

2-3. (Canceled).

4. (Previously Presented): The method according to claim 1, wherein the composition comprises 0.1% to 1% by weight of adenosine with respect to the total composition weight.

5-9. (Canceled).

10. (Currently Amended): The method according to Claim 1, comprising topically applying to the skin an amount of said composition effective to provide a relaxing effect on contractile fibroblasts associated with the expression lines, thereby softening the expression lines.

11-12. (Canceled).

13. (Previously Presented): The method according to claim 10, wherein the composition comprises 0.1% to 1% by weight of adenosine with respect to the total composition weight.

14-18. (Canceled).

19. (Currently Amended): The method of Claim 1, wherein said composition further comprises at least one adenosine analogue compound selected from the group consisting of an agonist of an adenosine receptor, a compound which increases intra- or extra-cellular adenosine levels, 2'-deoxyadenosine, 2',3'-isopropoylidene adenosine, toyocamycin, 1-methyladenosine, N-6-methyladenosine, adenosine N-oxide, 6-methylmercaptopurine riboside, 6-chloropurine riboside, 5'-adenosine monophosphate, 5'-adenosine diphosphate, 5'-adenosine triphosphate, phenylisopropyl adenosine, 1-methylisoguanosine, N⁶-cyclohexyl adenosine, N⁶-cyclopentyl adenosine, 2-chloro-N-6-cyclopentyladenosine, 2-chloroadenosine, N⁶-phenyladenosine, 2-phenylaminoadenosine, MECA, N⁶-phenethyladenosine, 2-p-(2-carboxyethyl)-phenethyl-amino-5'-N-ethylcarboxamido-adenosine, N-ethylcarboxamido-adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, DPMA, metrifudil, erythro-9-(2-hydroxy-3-nonyl) adenine, iodotubercidin, salts of adenosine and esters of adenosine.

20. (Currently Amended): The method of Claim 10, wherein said composition further comprises at least one adenosine analogue compound selected from the group consisting of an agonist of an adenosine receptor, a compound which increases intra- or extra-cellular adenosine levels, 2'-deoxyadenosine, 2',3'-isopropoylidene adenosine, toyocamycin, 1-methyladenosine, N-6-methyladenosine, adenosine N-oxide, 6-methylmercaptopurine riboside, 6-chloropurine riboside, 5'-adenosine monophosphate, 5'-adenosine diphosphate, 5'-adenosine triphosphate, phenylisopropyl adenosine, 1-methylisoguanosine, N⁶-cyclohexyl adenosine, N⁶-cyclopentyl adenosine, 2-chloro-N-6-cyclopentyladenosine, 2-chloroadenosine, N⁶-phenyladenosine, 2-phenylaminoadenosine, MECA, N⁶-phenethyladenosine, 2-p-(2-carboxyethyl)-phenethyl-amino-5'-N-ethylcarboxamido-adenosine, N-ethylcarboxamido-adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, DPMA, metrifudil, erythro-9-(2-hydroxy-3-nonyl) adenine, iodotubercidin, salts of adenosine and esters of adenosine.

Application No. 10/701,495
Response to Office Action dated June 11, 2009

MECA, N⁶-phenethyladenosine, 2-p-(2-carboxyethyl)-phenethyl-amino-5'-N-ethylcarboxamido-adenosine, N-ethylcarboxamido-adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, DPMA, metrifudil, erythro-9-(2-hydroxy-3-nonyl) adenine, iodotubercidin, salts of adenosine and esters of adenosine.

21. (Previously Presented): The method of claim 1, comprising topically applying to the skin an effective amount of said composition to reduce laugh lines and/or reduce frown lines.

22-23. (Canceled).

24. (New) The method of claim 19, wherein the composition further comprises at least one adenosine compound selected from the group consisting of an agonist of an adenosine receptor and a compound which increases intra- or extra-cellular adenosine levels.

25. (New) The method of claim 19, wherein the composition further comprises at least one adenosine compound selected from the group consisting of: 2'-deoxyadenosine; 2',3'-isopropoylidene adenosine; toyocamycin; 1-methyladenosine, N-6-methyladenosine; adenosine N-oxide; 6-methylmercaptopurine riboside; 6-chloropurine riboside; 5'-adenosine monophosphate; 5'-adenosine diphosphate and 5'-adenosine triphosphate.

26. (New) The method of claim 19, wherein the composition further comprises at least one adenosine compound selected from the group consisting of phenylisopropyl adenosine, 1-methylisoguanosine, N⁶-cyclohexyl adenosine, N⁶-cyclopentyl adenosine, 2-chloro-N-6-cyclopentyladenosine, 2-chloroadenosine, N⁶-phenyladenosine, 2-phenylaminoadenosine, MECA, N⁶-phenethyladenosine, 2-p-(2-carboxyethyl)-phenethyl-

Application No. 10/701,495
Response to Office Action dated June 11, 2009

amino-5'-N-ethylcarboxamido-adenosine, N-ethylcarboxamido-adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, DPMA and metrifudil.

27. (New) The method of claim 19, wherein the composition further comprises at least one adenosine compound selected from the group consisting of erythro-9-(2-hydroxy-3-nonyl) adenine and iodotubercidin.

28. (New) The method of claim 19, wherein the composition further comprises at least one adenosine compound selected from the group consisting of adenosine and esters of adenosine.

29. (New): The method according to Claim 1, comprising topically applying to the skin an amount of said composition effective to provide a relaxing effect on dermal contractile cells associated with the expression lines, thereby softening the expression lines.

30. (New): The method according to Claim 1, wherein the expression lines are at least one selected from the group consisting of crow's feet, nasogenic furrows, inter-eyebrow lines and forehead lines.

31. (New): The method according to claim 29, wherein the composition comprises 0.1% to 1% by weight of adenosine with respect to the total composition weight.